Prof Klaus Pantel

Chairman of the Institute of Tumour Biology at the University Medical Center Hamburg-Eppendorf.

Prof Klaus Pantel is Chairman of the Institute of Tumour Biology at the University Medical Center Hamburg-Eppendorf. The institute is part of the Centre of Experimental Medicine and the University Cancer Center Hamburg (UCCH). Prof Pantel graduated in 1986 from Cologne University in Germany and completed his thesis on mathematical modelling of haematopoiesis in 1987. After his postdoctoral period in the USA on hematopoietic stem cell regulation (Wayne State University, Detroit), he performed research at the Institute of Immunology, University of Munich for 10 years.

The pioneer work of Prof Pantel in the field of cancer micrometastasis, circulating tumor cells and circulating nucleic acids (ctDNA, microRNAs) is reflected by more than 400 publications in excellent high ranking biomedical and scientific journals (incl. NEJM, Lancet, Nature Journals, Cancer Cell, Science Translational Medicine, Cancer Discovery, PNAS, JCO, JNCI, Cancer Res.) and has been awarded the AACR Outstanding Investigator Award 2010, German Cancer Award 2010, and two ERC Advanced Investigator Grants 2011 and 2019. Moreover, Prof Pantel coordinates the European IMI consortium CANCER-ID (www.cancer-id.eu) on blood-based “Liquid Biopsies” in lung and breast cancer comprising 37 partner institutions from academia, non-profit organizations and industry.

v1; Portrait; Porträt; Prof. Dr. med. Klaus Pantel; Institutsdirektor; Zentrum für Experimentelle Medizin; Institut für Tumorbiologie

Title: Liquid Biopsies: From Discovery to Clinical Implementation

  • The analysis of circulating tumor cells (CTCs) and tumor cell products (DNA,RNA, extracellular vesicles) released into the blood provides clinically relevant information as “liquid biopsy”.
  • Liquid biopsy analyses with validated platforms provides information on:
    • early detection of cancer;
    • identification of cancer patients at risk to develop relapse (prognosis);
    • monitoring of tumor evolution;
    • and therapeutic targets or mechanisms of resistance on metastatic cells.
  • Metastatic cells might have unique characteristics that can differ from the bulk of cancer cells in the primary tumor currently used for stratification of patients to systemic therapy.
  • Liquid biopsy can be used to improve the management of individual cancer patients and contribute to personalized medicine.
  • CTCs are complementary to other liquid biopsy biomarkers.
  • Validation of liquid biopsy assays is essential and currently performed by the EU/IMI consortium CANCER-ID (www.cancer-id.eu) and ELBS (European Liquid Biopsy Society).

Show more
Show less

Presentation not available

On the Web

https://www.uke.de/

On LinkedIn

Visit profile